Eliquis Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast - 2022 to 2028

The global eliquis market is anticipated to grow at a significant CAGR of 4.8% during the forecast period (2022-2028). Eliquis (apixaban) is a prescription pharmaceutical used to lower the risk of stroke and blood clots in patients with a trial fibrillation, additionally; it lowers the risk of blood clots formation in the legs and lungs of persons who have recently had hip or knee replacement surgery. Apixaban is an anticoagulant licensed by the Food and Drug Administration (FDA) for the treatment of venous thromboembolic events (VTE) that occur within a vein. VTE can happen without any warning signs or symptoms. The rising occurrence of VTE is expected to boost the market. According to the published by the American Heart Association in 2017, VTE affects around300,000 and 600,000 Americans each year. Pulmonary embolism (PE) is another most prevalent and preventable cause of death among hospital patients in the US. The two biggest public health issues are VTE and PE.

A full report of Eliquis Market is available at: https://orionmarketreports.com/eliquis-market/102861/  

Eliquis enables individuals with non-valvular a trial fibrillation to reduce their risk of stroke and embolism. Patients who have had knee or hip replacement surgery are given this medicine as a prophylactic to prevent deep vein thrombosis, which can lead to pulmonary embolism. Eliquis is the third oral anticoagulant that is not a vitamin K antagonist and is utilized in clinical practice. When compared to warfarin, the regular dose of eliquis is more effective in reducing thromboembolic events.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

In September 2020, Indoco Remedies' stock rose 19% in intraday trade on the BSE after the firm announced that its blood-thinning medicine Apixaban tablets had been approved by the USFDA. The authorized medicine is therapeutically equivalent to Bristol-Myers Squibb's Eliquis, which is mentioned as a reference drug.
In January 2020, LUNAC Therapeutics (LUNAC) has announced that it has received funding of $3.54 million from the University of Leeds in the first closure of a Series A fundraising transaction. Epidarex Capital and the University of Leeds were the driving forces behind the investment. The firm is concentrating on developing next-generation anticoagulants. To lessen the risk, the organization is focusing on the coagulation cascade at the level of Factor XII. Additionally, the development of improved anticoagulants allows patients and healthcare providers to have more options and raise demand. Apixaban (ELIQUIS) was approved by the FDA for a range of diseases after a significant clinical research effort. Apixaban is a powerful anticoagulant that works by preventing particular blood clotting proteins from forming.
In December 2019, the USFDA had accepted two applications for the first generic eliquis (Apixaban) tablets to enable patients with non-valvular a trial fibrillation to minimize their risk of stroke and systemic embolism.

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Application
By Distribution Channel
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
·         Competitive Landscape-Amtec Health Care Pvt. Ltd., Mehta API Pvt Ltd., Zhejiang Tianyu Pharmaceutical Co.,Ltd., Element Chemilink Pvt. Ltd., and Teva Pharmaceutical Industries Ltd., among others.

 

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Eliquis Market Report by Segment

By Application

Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.